CDNA
Caredx Inc
NASDAQ · Biotechnology
$19.47
+1.12 (+6.10%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 303.20M | 291.43M | 315.95M | 329.37M | 271.09M |
| Net Income | 47.73M | 41.29M | -68,414,801 | -60,795,749 | -51,228,951 |
| EPS | — | — | — | — | — |
| Profit Margin | 15.7% | 15.0% | -21.7% | -18.5% | -18.9% |
| Rev Growth | +4.0% | +4.0% | -5.3% | -9.3% | +22.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 334.94M | 344.44M | 346.18M |
| Total Equity | — | — | 404.03M | 455.35M | 445.81M |
| D/E Ratio | — | — | 0.83 | 0.76 | 0.78 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 39.62M | 36.18M | -82,367,409 | -79,903,104 | -63,531,119 |
| Free Cash Flow | — | — | -65,793,319 | -60,969,564 | -57,293,986 |